Enoxaparin as Treatment for Vulvodynia

The investigators hypothesize that injections of Low molecular weight heparin (LMWH) [enoxaparin] will reduce pain in women with vulvodynia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vulvodynia Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Urogenital Diseases Vulvar Diseases

Age range

19 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Western Galilee Hospital- Nahariya

Nahariya, 22100, Israel

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

women with vulvodynia

Exclusion criteria

women without vulvodynia

Treatment and study plan

Clexane (enoxaparin)

Drug

One arm receives enoxoparin, second arm receives saline

Primary outcomes

vestibular pain

Time frame: one year

Sponsors and collaborators

Lead sponsor

Western Galilee Hospital-Nahariya

Other Gov

Registry information

Official study title

Enoxaparin as Treatment for Vulvar Vestibulitis Syndrome - Vulvodynia

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2011
First posted: Apr 2, 2009
Registry last updated: May 20, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed